These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 19147690

  • 1. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
    Zhu AX, Clark JW.
    Oncologist; 2009 Jan; 14(1):67-9. PubMed ID: 19147690
    [No Abstract] [Full Text] [Related]

  • 2. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M.
    Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
    [Abstract] [Full Text] [Related]

  • 3. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B, Di Maio M.
    J Clin Gastroenterol; 2009 Jan; 43(5):389-90. PubMed ID: 19564813
    [No Abstract] [Full Text] [Related]

  • 4. Hepatocellular carcinoma: sorafenib before liver transplantation?
    Braillon A.
    Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
    [No Abstract] [Full Text] [Related]

  • 5. Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?
    Abou-Alfa GK.
    Oncologist; 2009 Jan; 14(1):92-4. PubMed ID: 19144679
    [No Abstract] [Full Text] [Related]

  • 6. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.
    Cabibbo G, Rolle E, De Giorgio M, Genco C, Pressiani T, Spada F, Sacco R, HCC Working Group.
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1807-16. PubMed ID: 22049974
    [Abstract] [Full Text] [Related]

  • 7. Sorafenib for HCC: a pragmatic perspective.
    Razumilava N, Gores GJ.
    Oncology (Williston Park); 2011 Mar; 25(3):300, 302. PubMed ID: 21548475
    [No Abstract] [Full Text] [Related]

  • 8. Sorafenib in hepatocellular carcinoma.
    Josephs DH, Ross PJ.
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Selection of patients with hepatocellular carcinoma for sorafenib.
    Abou-Alfa GK.
    J Natl Compr Canc Netw; 2009 Apr; 7(4):397-403. PubMed ID: 19406040
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sorafenib for liver cancer: the horizon broadens.
    Johnson P, Billingham L.
    Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.